healthŌme

What healthŌme does

healthŌme, Inc. (rebranded Kadance, Inc. effective January 8, 2025) is a genomics-based precision health management company that designs and delivers omics-based products embedded as riders in critical illness and life insurance policies. Founded in 2021 and headquartered at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, the company operates a B2B2C model in which life and critical illness insurance carriers license its programs and distribute them to policyholders; Chubb Workplace Benefits holds the exclusive worksite distribution partnership for the flagship Cancer Advocate Plus product, and Hannover Re US serves as reinsurer.

The product portfolio centers on the cancerōme® end-to-end cancer management program, which combines heritable cancer risk screening (healthŌme One™ test of 30 cancer-risk genes), pharmacogenomic drug-response testing, expert medical review, 1:1 oncology nurse navigation, clinical trial identification, and DNA-based recurrence monitoring. In March 2024, the company expanded into medication safety via a partnership with GalenusRx integrating the APPRAISE™ drug-drug, drug-gene, and drug-disease interaction platform. The May 2023 acquisition of Kailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory and NGS reagent supplier, provides vertically integrated lab capabilities; Kailos also serves third-party clients. Supporting clinical services are delivered through partners including SteadyMD (telemedicine/genetic counseling), Protean Biodiagnostics, and Access Genetics.

The company monetizes through licensing fees and per-policyholder program fees paid by insurance carriers (subscription/recurring model), supplemented by third-party lab services revenue from Kailos. The preferred seed funding round closed in May 2024 (~$8.44M) was co-led by American Family Ventures and AllegisNL Capital, with Hannover Re as a strategic reinsurance partner; the company won the 2024 Global Innovation Award from the International Insurance Society, Insurance Thought Leadership, and Lloyd's. The leadership team comprises a CEO with healthcare and genomics commercialization background, a CCO with genomics-industry tenure (ex-Illumina, Applied Biosystems, St. Jude), a COO ex-Hannover Re, the former CTO of Kailos Genetics as CTO, and a former Illinois/Connecticut Commissioner of Insurance as Board Chair.

Name

healthŌme

Legal name

healthOme, Inc.

Website

https://healthome.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

healthŌme (now Kadance, Inc.) designs genomics-based precision health programs — heritable cancer risk screening, pharmacogenomic testing, and end-to-end cancer management — embedded as riders in critical illness and life insurance policies distributed through carrier partners such as Chubb.

Ownership category

akta.pro rank

Product category

Genomics-Based Precision Health Management for Insurance

NAICS

Direct Health and Medical Insurance Carriers (524114), Direct Life Insurance Carriers (524113), Insurance Agencies and Brokerages (524210)

SIC

Accident & Health Insurance (6321), Insurance Agents, Brokers & Service (6411), Services-Health Services (8000)

akta.pro primary industry

Worksite Cancer / Specified Disease Insurance (FSAIAMAI)

akta.pro secondary industry

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

Keywords

• Genomics precision health
• Critical illness insurance
• Life insurance riders
• Pharmacogenomic testing
• Cancer risk screening

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. B2B2C Insurance Carrier Licensing & Program Fees: healthŌme designs and delivers tech-enabled precision health management programs through a network of life and critical illness insurance carriers. Carriers embed healthŌme products as riders to existing policies or as standalone disease-specific policies. Revenue is derived from licensing fees or per-policyholder program fees paid by insurance carriers. The company provides heritable cancer risk screening, pharmacogenomic testing, precision cancer management, and nurse navigation services to policyholders on behalf of carriers.
2. Kailos Genetics Laboratory Services: Kailos Genetics, a wholly-owned subsidiary of healthŌme, provides genetic testing laboratory services and clinical grade laboratory reagents for next-generation sequencing to the marketplace, including third-party clients beyond healthŌme's insurance partnerships.
3. GalenusRx Partnership - Medication Safety Program: Through the partnership with GalenusRx, policyholder access to pharmacogenomic testing and precision clinical pharmacist consultations generates value through reduced adverse drug events and improved medication management outcomes for insurance carriers.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

healthŌme creates omics-based products for the critical illness and life insurance industry, integrating heritable cancer risk screening, pharmacogenomic testing, precision cancer management (nurse navigation, expert medical review, clinical trial matching), DNA-based recurrence monitoring, and medication safety analysis into insurance policies as riders. Programs are licensed to insurance carriers (including Chubb Workplace Benefits) who deliver them to policyholders as day-one living benefits, supported by the company's in-house CLIA-certified and CAP-accredited Kailos Genetics laboratory.

Product overview

healthŌme is a genomics-based precision health management platform operating at the intersection of life insurance, life science, and health management. The company offers a unified platform with multiple integrated products: the core cancerŌme® program provides end-to-end cancer management combining hereditary cancer risk screening (healthŌme One™ test), pharmacogenomic testing, and precision cancer management with genomic profiling and nurse navigation. Kadance serves as the consumer-facing brand for these services. The product portfolio also includes a Personalized Medication Safety Program powered by GalenusRx's APPRAISE™ platform. The company operates through a fully integrated in-house genetics lab (Kailos Genetics) and distributes through life and critical illness insurance carriers, with products offered as riders to existing insurance policies. Following the January 2025 rebrand, the company operates under Kadance, Inc.

Differentiator

Problem solved

Functional benefit

Brands

• Kadance: Insurance program providing DNA-powered health management with focus on cancer management and pharmacogenomics.
• cancerŌme

Products and services

• cancerōme® Cancer Management Program A first-of-its-kind, patent-pending omics-based insurance program delivering end-to-end cancer management from heritable risk screening through diagnosis, treatment, and recurrence monitoring. Designed for individual policyholders of participating life and critical illness insurance policies and licensed to insurance carriers as a differentiated rider offering.
• healthōme One™ Heritable Cancer Risk Screening Test Clinical-grade at-home genetic screening test analyzing 30 different inherited genes known to increase cancer risk. Includes genetic counseling and a personalized action plan for individuals identified with above-average cancer risk. Offered as a day-one benefit to eligible insurance policyholders.
• Pharmacogenomic (PGx) Drug Response Testing Clinical-grade pharmacogenomic testing that indicates how an individual will respond to particular medications, the likelihood of adverse drug reactions, and optimal medication dosage based on genetic profile. Approximately 95% of the population has a genetic variant affecting medication metabolism. Provided to eligible insurance policyholders.
• DNA-based Cancer Recurrence Monitoring Blood-based genetic test that tracks tiny traces of cancer in the blood to detect returning cancer earlier than traditional medical testing. Used during the cancer survivorship and recovery phase for policyholders who have completed initial treatment.
• Personalized Medication Safety Program Genomics-based medication safety program that integrates a policyholder's pharmacogenomic test results with GalenusRx's APPRAISE™ medication-safety platform. Produces a Personalized Medication Safety Plan via drug-drug, multi-drug, drug-gene, and drug-disease interaction analysis, and includes precision clinical pharmacist telehealth consultations to reduce adverse drug events.
• Kailos Genetics Laboratory Services Clinical-grade genetic testing laboratory services and supply of clinical-grade laboratory reagents for next-generation sequencing, provided by Kailos Genetics (a wholly-owned subsidiary of healthŌme). Serves both healthŌme's insurance policyholder programs and third-party clients in the broader genetic testing market.

Quantifiable outcome

• Five-year survival rate for early-stage cancers is 91.1% compared to 30.6% for late-stage cancers — early detection through genetic screening dramatically improves survivability
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability7 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Hannover Re AmericacoreStrategic or Co-development Partner · 22 May 2024Hannover Re is the reinsurer for healthŌme's first-of-its-kind cancer management program. Vice President Julian Whitekus serves as board observer. Hannover Re collaborated with healthŌme on integrating genomics-based services into critical illness and life insurance products, demonstrating how the partnership empowers insurers to improve product offerings and enhance member engagement.
• GalenusRx, Inc.coreTechnology or Integration · 20 March 2024Strategic partnership to launch a genomics-based personalized medication safety program. GalenusRx provides its APPRAISE™ proprietary medication safety technology and precision clinical pharmacists who deliver medication safety insights and consultations. The partnership integrates GalenusRx's clinical pharmacy expertise with healthŌme's pharmacogenomic testing and policyholder platform to reduce adverse drug events for policyholders.
• Kailos Genetics, LLCcoreOEM/ Whitelabel/ Licensing Partner · 31 May 2023Kailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory and supplier of clinical grade laboratory reagents for next-generation sequencing, was acquired by healthŌme on May 31, 2023, and became a wholly-owned subsidiary. Kailos continues to provide its full range of genetic testing services and reagents to the marketplace in addition to serving healthŌme. David Kloske, former CTO of Kailos Genetics, became CTO of healthŌme.
• Chubb Workplace BenefitscoreChannel Partner/ Reseller/ Distributor · 22 February 2023Exclusive distribution partnership for Cancer Advocate Plus, a first-of-its-kind genetics-based cancer program distributed through Chubb's voluntary benefits worksite channel to employees of middle-market and large companies. Chubb provides insurance underwriting while healthŌme delivers all genomics services including heritable cancer risk screening, pharmacogenomic testing, and precision cancer management.
• HudsonAlpha Institute for BiotechnologyminorStrategic or Co-development PartnerhealthŌme and Kailos Genetics are both resident associate companies at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. HudsonAlpha provides laboratory facilities and an ecosystem of biotech innovation. Founder Jim Hudson noted the strategic value of combining two HudsonAlpha associate companies to advance healthcare solutions.

Scale indicators5 records

Recent moves7 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/healthOme_Inc
• Facebookfacebook.com/healthomeinc
• LinkedInlinkedin.com/company/healthomeinc
• Instagraminstagram.com/healthome_inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about healthŌme